Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, announced terms for its IPO on Monday.
The Montreal, Canada-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Milestone Pharmaceuticals would command a fully diluted market value of $378 million.
Milestone Pharmaceuticals was founded in 2003 and plans to list on the Nasdaq under the symbol MIST. Jefferies, Cowen and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of May 6, 2019.
